Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.74 |
| ▸ | RHEB | Q15382 | 10/20 | 0.57 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727389 | 0.85 | GRIN1 (1.00) | GRIN1RHEBEIF4A3GRIN2DGRIN3B | |
| SCHEMBL29531428 | 0.85 | GRIN1 (1.00) | GRIN1RHEBEIF4A3GRIN2DGRIN3B | |
| SCHEMBL20505089 | 0.84 | GRIN1 (0.72) | GRIN1RHEBEIF4A3GRIN2DGRIN3B | |
| SCHEMBL22529402 | 0.84 | GRIN1 (0.72) | GRIN1RHEBEIF4A3GRIN2DGRIN3B | |
| SCHEMBL19624732 | 0.81 | GRIN1 (0.68) | GRIN1RHEBEIF4A3GRIN2DGRIN3B | |
| SCHEMBL23111930 | 0.80 | GRIN1 (0.66) | GRIN1RHEBEIF4A3GRIN2DGRIN3B | |
| SCHEMBL9433015 | 0.80 | GRIN1 (0.66) | GRIN1RHEBEIF4A3GRIN2DGRIN3B | |
| SCHEMBL18510263 | 0.80 | GRIN1 (0.66) | GRIN1RHEBEIF4A3GRIN2DGRIN3B | |
| SCHEMBL23147814 | 0.79 | GRIN1 (0.47) | GRIN1RHEBEIF4A3GRIN2DGRIN3B | |
| SCHEMBL7951008 | 0.77 | GRIN1 (0.62) | GRIN1RHEBEIF4A3GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| EP-2166856-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | BIONDI RICARDO M | 2007-02-08 | — | — | US | disclosed |
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | BIONDI RICARDO M | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | CYP7A1, UGT1A1, CYP2F1 | GRIN1 3072/4885RHEB 3294/4885EIF4A3 2144/4885 |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | GRIN1 2872/4885RHEB 1258/4885EIF4A3 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.